Minute Insight: Sema4 To Acquire Genomics Company GeneDx For $623M To Strengthen Clinical Data Platform
Executive Summary
Genetic testing company Sema4 announced plans to buy GeneDx to strengthen Sema4’s health intelligence and genomic screening offers. The combined company is expected to generate $350m in pro forma 2022 revenue.
You may also be interested in...
Blank Check Companies’ Hunt For Innovative Medtech Start-Ups To Heat Up Further, Experts Predict
As the SPAC boom continues, innovative medtechs are expected to become acquisition targets.
Menopause Research To Benefit From White House Initiative To Bolster Women’s Health
Women’s health leaders in the menopause space have high hopes that President Biden’s executive order will provide dollars for more research on how hormone therapy can prevent disease and draw attention to the need for provider education on menopausal symptoms.
BD’s CTO Beth McCombs Discusses Key Initiatives – AI/Gen AI; DE&I Strategy; Succession Planning
BD CTO Beth McCombs discusses her role in driving innovation, including the integration of AI and generative AI to create efficiencies, and passion for creating a culture of inclusion, diversity and equity.